Physician profile
Robert D Mccray
NPI 1477653236
$1,985.23
in general payments reported to CMS, 2019-2025
23 companies · $338 in 2025
The $338 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2020: $403 · 2021: $260 · 2022: $57.36 · 2023: $51.24 · 2024: $310 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $699.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $503.25 | 2019-2025 | |
| Amgen INC. | $218.05 | 2019-2025 | Repatha, Repatha |
| Scpharmaceuticals INC. | $204.52 | 2024-2025 | |
| Astellas Pharma US INC | $135.82 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $128.90 | 2019-2020 | |
| Pfizer INC. | $115.05 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $108.66 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $81.37 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $72.00 | 2019-2021 | |
| Philips North America LLC | $60.70 | 2022-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Ck6) Holter |
| Baxter Healthcare | $52.75 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Irhythm Technologies, INC. | $46.56 | 2020-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $41.14 | 2019-2025 | Lifevest |
| Portola Pharmaceuticals, LLC | $34.55 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.55 | 2019-2025 | Jardiance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $28.69 | 2020-2021 | |
| Lundbeck LLC | $21.27 | 2020 | |
| Amarin Pharma, INC. | $19.31 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $18.44 | 2024 | Arcalyst |
| Nuwellis, INC. | $17.49 | 2019 | |
| Bridgebio Pharma, INC. | $16.75 | 2025 | Attruby |
| Lilly USA, LLC | $12.80 | 2019 | |
| Bardy Diagnostics, INC. | $12.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mccray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.